A Phase I, Open-label, Randomized, Single Dose, Five-period, Crossover, Single Center Trial to Assess the Relative Bioavailability of the 150 mg ODT Formulation of L-PZQ (MSC2499550A) vs the Current 500 mg PZQ Commercial Racemate Tablet Formulation in Healthy Male Volunteers

Trial Profile

A Phase I, Open-label, Randomized, Single Dose, Five-period, Crossover, Single Center Trial to Assess the Relative Bioavailability of the 150 mg ODT Formulation of L-PZQ (MSC2499550A) vs the Current 500 mg PZQ Commercial Racemate Tablet Formulation in Healthy Male Volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 20 Oct 2015

At a glance

  • Drugs Praziquantel (Primary)
  • Indications Schistosomiasis
  • Focus Pharmacokinetics
  • Sponsors Merck KGaA
  • Most Recent Events

    • 20 Jan 2015 Status changed from not yet recruiting to completed as reported by ClinicalTrials.gov record.
    • 29 Oct 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top